Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action.[2][3] The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.[2] The company has sixteen products in its pipeline, in various stages of development.[2]
More information Product, Indication ...
| Product | Indication | Development phase | Notes |
| ARO-HBV[2] | Hepatitis B | In clinic, phase 2 | Licensed with Janssen, Phase 2 |
| ARO-AAT[2] | Alpha-1 antirypsin deficiency | In clinic, phase 3 | Orphan Drug designation, partnered with Takeda |
| ARO-APOC3[2] | Hypertriglyceridemia | Phase 2, 3 | Orphan Drug designation, Fast Track Designation, Phase 3 for FCS, Phase 2 for expanded populations |
| ARO-HIF2[2] | Renal cell carcinoma | Preclinical |
Second generation being worked on presumably |
| ARO-ENaC[2] | Cystic fibrosis | Preclinical |
Second generation being worked on in preclinic |
| ARO-ANG3[2] | Dyslipidemia | In clinic, Phase 2 | Orphan Drug designation |
| Olpasiran/ AMG 890[2] | Cardiovascular disease | In clinic, phase 3 | Partnered with Amgen |
| ARO-PNPLA3 |
NASH |
In clinic, Phase 1 |
License returned to ARWR |
| ARO-HSD |
NASH |
In clinic, Phase 1 |
Licensed to GSK |
| ARO-C3 |
Complement Mediated Disease |
In clinic, Phase 1 |
|
| ARO-MUC5AC |
Muco-obstructive |
In clinic, Phase 1 |
|
| ARO-RAGE |
Inflammatory |
In clinic, Phase 1 |
|
| ARO-MMP7 |
Idiopathic Pulmonary Fibrosis |
In clinic, Phase 1 |
|
| ARO-COV |
Covid-19 |
Preclinical |
|
| ARO-DUX4 |
FSHD |
Preclinical |
|
| HZN-457 |
Gout |
In clinic, Phase 1 |
Partnered with Horizon |
Close
Quick Facts Company type, Traded as ...
Arrowhead Pharmaceuticals, Inc. |
| Company type | Public |
|---|
| |
|---|
| Industry | Biotechnology |
|---|
| Founded | 1 January 2004  |
|---|
| Headquarters | Pasadena, California, U.S. |
|---|
Key people | Christopher Anzalone, Ph.D., president and chief executive officer
Javier San Martin, M.D., Chief Medical Officer
Ken Myszkowski, MBA, CPA, chief financial officer
James Hamilton, M.D., MBA, Chief Discovery and Translational Medicine |
|---|
| Revenue |  $243.2 million(2022)[1] |
|---|
Number of employees | 376 |
|---|
| Website | arrowheadpharma.com |
|---|
Close
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.[4][5]
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.[6]
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.[7]
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. As part of the deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three more RNA interference (RNAi) therapeutics against new targets to be selected by Janssen.[8]
